Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Cancer cell - 1 Feb 2005

Weisberg Ellen, Manley Paul W, Breitenstein Werner, Brüggen Josef, Cowan-Jacob Sandra W, Ray Arghya, Huntly Brian, Fabbro Doriano, Fendrich Gabriele, Hall-Meyers Elizabeth, Kung Andrew L, Mestan Jürgen, Daley George Q, Callahan Linda, Catley Laurie, Cavazza Cara, Azam Mohammad, Mohammed Azam, Neuberg Donna, Wright Renee D, Gilliland D Gary, Griffin James D

Abstract excerpt

The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 <30 nM), which is significantly more potent than imatinib, and active against a number of imatinib-resistant Bcr-Abl mutants. Crystallographic analysis of Abl-AMN107 complexes provides a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Inhibitory Concentration 50

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Models, Chemical

Share to Mycoplasma

Share to Retroviridae

Source

Identifiers

PMID: 15710326
DOI: 10.1016/j.ccr.2005.01.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.PMID 15710326Read ↗

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblSemantic proximity Read ↗

AMN107: tightening the grip of imatinib.Semantic proximity Read ↗

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.Semantic proximity Read ↗

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.Semantic proximity Read ↗

The second generation of BCR-ABL tyrosine kinase inhibitors.Semantic proximity Read ↗

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.Semantic proximity Read ↗

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.Semantic proximity Read ↗

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid LeukemiaSemantic proximity Read ↗

Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignanciesSemantic proximity Read ↗

HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistanceSemantic proximity Read ↗

Overriding imatinib resistance with a novel ABL kinase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.